Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

AbbVie Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

	Jun 30, 2026	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021
Short-term borrowings	—)	—)	2,499)	3,790)	5,556)	1,593)	—)	—)	—)	3)	—)	2)	—)	1)	1)	10)	17)	12)	14)	16)	17)	9)
Current portion of long-term debt	8,341)	8,326)	6,056)	1,982)	1,966)	3,769)	6,804)	12,570)	12,586)	10,193)	7,191)	5,113)	5,203)	2,800)	4,135)	9,197)	11,913)	9,940)	12,481)	6,656)	7,884)	11,338)
Accounts payable and accrued liabilities	33,301)	33,774)	34,734)	33,619)	32,245)	31,041)	31,945)	30,492)	29,329)	31,326)	30,650)	29,658)	27,036)	24,789)	25,402)	23,505)	22,543)	22,569)	22,699)	21,861)	20,783)	20,604)
Current liabilities	41,642)	42,100)	43,289)	39,391)	39,767)	36,403)	38,749)	43,062)	41,915)	41,522)	37,841)	34,773)	32,239)	27,590)	29,538)	32,712)	34,473)	32,521)	35,194)	28,533)	28,684)	31,951)
Long-term debt, excluding current portion	62,481)	64,532)	58,941)	62,971)	62,959)	64,527)	60,340)	58,509)	58,048)	63,805)	52,194)	55,631)	55,812)	59,292)	59,135)	60,399)	61,002)	63,522)	64,189)	74,049)	74,237)	74,183)
Deferred income taxes	2,277)	2,332)	2,389)	2,480)	2,554)	2,582)	2,579)	2,749)	2,726)	2,722)	1,952)	2,044)	2,124)	2,110)	2,190)	1,972)	2,255)	2,831)	3,009)	3,602)	3,661)	3,768)
Other long-term liabilities	34,603)	34,111)	32,569)	31,655)	32,040)	31,191)	30,129)	33,031)	32,427)	32,778)	32,327)	31,644)	32,294)	32,249)	30,655)	30,215)	30,768)	28,023)	28,701)	29,097)	28,796)	26,866)
Long-term liabilities	99,361)	100,975)	93,899)	97,106)	97,553)	98,300)	93,048)	94,289)	93,201)	99,305)	86,473)	89,319)	90,230)	93,651)	91,980)	92,586)	94,025)	94,376)	95,899)	106,748)	106,694)	104,817)
Total liabilities	141,003)	143,075)	137,188)	136,497)	137,320)	134,703)	131,797)	137,351)	135,116)	140,827)	124,314)	124,092)	122,469)	121,241)	121,518)	125,298)	128,498)	126,897)	131,093)	135,281)	135,378)	136,768)
Common stock, $0.01 par value	18)	18)	18)	18)	18)	18)	18)	18)	18)	18)	18)	18)	18)	18)	18)	18)	18)	18)	18)	18)	18)	18)
Common stock held in treasury, at cost	(10,618)	(10,611)	(9,146)	(9,143)	(9,147)	(9,137)	(8,201)	(7,848)	(7,838)	(7,829)	(6,533)	(6,525)	(6,528)	(6,524)	(4,594)	(4,590)	(4,591)	(4,585)	(3,143)	(3,020)	(3,022)	(3,017)
Additional paid-in-capital	23,156)	22,962)	22,495)	22,291)	21,987)	21,808)	21,333)	21,160)	20,879)	20,656)	20,180)	20,021)	19,839)	19,619)	19,245)	19,056)	18,906)	18,731)	18,305)	18,108)	17,936)	17,712)
Retained earnings (accumulated deficit)	(17,333)	(17,872)	(15,493)	(14,234)	(11,503)	(9,527)	(7,900)	(4,964)	(3,768)	(2,384)	(1,000)	933)	1,789)	2,393)	4,784)	4,953)	3,516)	5,103)	3,127)	1,600)	740)	2,292)
Accumulated other comprehensive loss	(1,158)	(1,153)	(1,144)	(1,574)	(1,538)	(1,742)	(1,925)	(2,334)	(2,513)	(2,454)	(2,305)	(2,353)	(2,252)	(2,232)	(2,199)	(3,443)	(3,196)	(2,984)	(2,899)	(3,156)	(3,103)	(3,295)
Stockholders’ equity (deficit)	(5,935)	(6,656)	(3,270)	(2,642)	(183)	1,420)	3,325)	6,032)	6,778)	8,007)	10,360)	12,094)	12,866)	13,274)	17,254)	15,994)	14,653)	16,283)	15,408)	13,550)	12,569)	13,710)
Noncontrolling interest	47)	44)	42)	43)	45)	42)	39)	39)	43)	40)	37)	35)	32)	29)	33)	33)	35)	31)	28)	27)	25)	23)
Total equity (deficit)	(5,888)	(6,612)	(3,228)	(2,599)	(138)	1,462)	3,364)	6,071)	6,821)	8,047)	10,397)	12,129)	12,898)	13,303)	17,287)	16,027)	14,688)	16,314)	15,436)	13,577)	12,594)	13,733)
Total liabilities and equity (deficit)	135,115)	136,463)	133,960)	133,898)	137,182)	136,165)	135,161)	143,422)	141,937)	148,874)	134,711)	136,221)	135,367)	134,544)	138,805)	141,325)	143,186)	143,211)	146,529)	148,858)	147,972)	150,501)

The financial position of the entity is characterized by a significant shift in its capital structure, transitioning from a positive equity position to a substantial stockholders' deficit over the analyzed period. While total liabilities have remained relatively stable, the erosion of equity is the most prominent trend, driven primarily by a collapse in retained earnings and an increase in treasury stock acquisitions.

Liability Trends and Composition: Total liabilities exhibited a general range between 121 billion and 143 billion US dollars. Current liabilities showed a gradual upward trajectory, rising from 31.9 billion US dollars in March 2021 to a peak of 43.1 billion US dollars in September 2024, before stabilizing around 41.6 billion US dollars by June 2026. This increase was largely fueled by a steady rise in accounts payable and accrued liabilities, which grew from 20.6 billion US dollars to 33.3 billion US dollars over the period.; Long-term debt, excluding the current portion, experienced fluctuations but remained the primary component of total liabilities. After a period of reduction from 74.2 billion US dollars in early 2021 to 52.2 billion US dollars in September 2023, the debt level increased again, fluctuating between 58 billion and 64 billion US dollars through June 2026.
Stockholders' Equity Analysis: A critical downward trend is observed in total equity, which declined from 13.7 billion US dollars in March 2021 to a deficit of 5.9 billion US dollars by June 2026. This transition into a negative equity position occurred between March 2025 and June 2025.; The deficit is primarily attributable to a sharp decline in retained earnings. Retained earnings shifted from a positive balance of 2.3 billion US dollars in March 2021 to an accumulated deficit of 17.3 billion US dollars by June 2026. This suggests that capital distributions or losses significantly exceeded net income during this timeframe.; Simultaneously, the cost of common stock held in treasury increased from 3.0 billion US dollars to 10.6 billion US dollars, indicating a sustained and aggressive share repurchase program that further reduced the total equity balance.
Solvency and Capital Structure Insights: The convergence of rising current liabilities and a deteriorating equity base indicates an increasing reliance on debt and external financing to support operations and shareholder returns. The emergence of a stockholders' deficit suggests a highly leveraged capital structure where total liabilities exceed total assets.; The stability of long-term liabilities in the face of vanishing equity suggests that the entity has maintained its debt obligations while aggressively returning capital to shareholders or absorbing significant losses, leading to a precarious balance sheet position by the end of the period.

AI Ask an analyst for more

Download chart

AbbVie Inc. (NYSE:ABBV)

Balance Sheet: Liabilities and Stockholders’ EquityQuarterly Data

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data